Dr Frias reported receiving grants from Eli Lilly and Company paid to his institution during the conduct of the study and grants, personal fees, or nonfinancial support from Boehringer Ingelheim, Pfizer, Merck, Altimmune, 89BIO, Akero, Carmot Therapeutics, Intercept, Janssen, Madrigal, Novartis, Eli Lilly, Sanofi, and Novo Nordisk outside the submitted work. Dr Rodbard reported receiving grants from Eli Lilly and Company during the conduct of the study and grants from Novo Nordisk, Sanofi, Medronic, Inversago, and Gan & Lee and personal fees from Bayer, Boehringer Ingelheim, and Pacira outside the submitted work. Dr Tofé reported receiving personal and research fees from Eli Lilly and Company and Novo Nordisk during the conduct of the study. Ms Sears reported being an employee of and shareholder in Eli Lilly and Company during the conduct of the study. Dr Huh reported being an employee of and shareholder in Eli Lilly and Company during the conduct of the study. Dr Fernández Landó reported owning stock in and receiving personal fees from Eli Lilly and Company as an employee during the conduct of the study and having a patent for US 9,474,780 B2 issued. Mr Patel reported receiving personal fees from and owning stock in Eli Lilly and Company during the conduct of the study and having a patent for US 9,474,780 B2 issued. 